Serotonergic drugs for the treatment of neuropsychiatric symptoms in dementia

Expert Review of Neurotherapeutics

Volumn 16, Issue 4, 2016, Pages 375-387

  Magierski, Radoslaw ^a   Sobow, Tomasz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

5 hydroxytryptamine; Alzheimer's disease; behavioral and psychological symptoms of dementia; dementia; neuropsychiatric symptoms; serotonin

Indexed keywords

NEUROTRANSMITTER; SEROTONIN RECEPTOR AFFECTING AGENT;

ALZHEIMER DISEASE; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; HUMAN; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROTRANSMISSION; PSYCHOPHARMACOTHERAPY; REVIEW; SEROTONINERGIC SYSTEM; BEHAVIOR; COGNITION DISORDERS; COMPLICATION;

BEHAVIORAL SYMPTOMS; COGNITION DISORDERS; DEMENTIA; HUMANS; SEROTONIN AGENTS;

EID: 84961215783     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2016.1155453     Document Type: Review

References (192)

1. Panza F, Solfrizzi V, Seripa D, et al. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease. Expert Opin Pharmacother. 2015;16(17):2581-2588.
2. Antonsdottir IM, Smith J, Keltz M, et al. Advancements in the treatment of agitation in Alzheimer's disease. Expert Opin Pharmacother. 2015;16(11):1649-1656.
3. Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan- quinidine on agitation in patients with alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242-1254.
4. Brown R, Howard R, Candy B, et al. Opioids for agitation in dementia. Cochrane Database Syst Rev. 2015;5:CD009705.
5. Trillo L, Das D, Hsieh W, et al. Ascending monoaminergic systems alterations in Alzheimer's disease. Translating basic science into clinical care. Neurosci Biobehav Rev. 2013;37(8):1363-1379.
6. Bali V, Chatterjee S, Carnahan RM, et al. Risk of dementia among elderly nursing home patients using paroxetine and other selective serotonin reuptake inhibitors. Psychiatr Serv. 2015;66(12):1333-1340.
7. Wang C, Gao S, Hendrie HC, et al. Antidepressant use in the elderly is associated with an increased risk of dementia. Alzheimer Dis Assoc Disord. 2015 Aug 19;1. [Epub ahead of print].
8. Goveas JS, Hogan PE, Kotchen JM, et al. Depressive symptoms, antidepressant use, and future cognitive health in postmenopausal women: the Women's Health Initiative Memory Study. Int Psychogeriatr. 2012;24(8):1252-1264.
9. Ravaglia G, Forti P, Lucicesare A, et al. Prevalent depressive symptoms as a risk factor for conversion to mild cognitive impairment in an elderly Italian cohort. Am J Geriatr Psychiatry. 2008;16(10):834-843.
10. Saczynski JS, Rosen AB, McCammon RJ, et al. Antidepressant use and cognitive decline: the health and retirement study. Am J Med. 2015;128(7):739-746.
11. Butters MA, Becker JT, Nebes RD, et al. Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry. 2000;157:1949-1954.
12. Mandelli L, Serretti A, Colombo C, et al. Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis. Psychiatry Clin Neurosci. 2006;60:598-604.
13. Culang ME, Sneed JR, Keilp JG, et al. Change in cognitive functioning following acute antidepressant treatment in late-life depression. Am J Geriatr Psychiatry. 2009;17:881-888.
14. Kessing LV, Forman JL, Andersen PK. Do continued antidepressants protect against dementia in patients with severe depressive disorder? Int Clin Psychopharmacol. 2011;26(6):316-322.
15. Carrière I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med. 2009;169 (14):1317-1324.
16. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401-407.
17. Ellul J, Archer N, Foy CM, et al. The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. J Neurol Neurosurg Psychiatry. 2007;78(3):233-239.
18. Rosenberg PB, Mielke MM, Han D, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. Int J Geriatr Psychiatry. 2012;27(12):1248-1257.
19. Li XL, Hu N, Tan MS, et al. Behavioral and psychological symptoms in Alzheimer's disease. Biomed Res Int. 2014;2014:927804.
20. Geda YE, Schneider LS, Gitlin LN, et al. Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement. 2013;9(5):602-608.
21. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.
22. Ford AH. Neuropsychiatric aspects of dementia. Maturitas. 2014;79 (2):209-215.
23. Borsje P, Wetzels RB, Lucassen PL, et al. The course of neuropsychiatric symptoms in community-dwelling patients with dementia: a systematic review. Int Psychogeriatr. 2015;27(3):385-405.
24. Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer's disease: systematic review and metaanalysis. J Affect Disord. 2015;190:264-271.
25. Selbæk G, Engedal K, Bergh S. The prevalence and course of neuropsychiatric symptoms in nursing home patients with dementia: a systematic review. J Am Med Dir Assoc. 2013;14 (3):161-169.
26. Okura T, Plassman BL, Steffens DC, et al. Prevalence of neuropsychatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study. J Am Geriatr Soc. 2010;58(2):330-337.
27. Thyrian JR, Eichler T, Hertel J, et al. Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care: results of the DelpHi-study. J Alzheimers Dis. 2015;46 (2):451-459.
28. Okura T, Plassman BL, Steffens DC, et al. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc. 2011;59 (3):473-481.
29. Peters ME, Schwartz S, Han D, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. 2015;172(5):460-465.
30. Moore A, Patterson C, Lee L, et al. Fourth Canadian consensus conference on the diagnosis and treatment of dementia: recommendations for family physicians. Can Fam Physician. 2014;60 (5):433-438.
31. Herrmann N, Lanctôt KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian consensus conference on the diagnosis and treatment of dementia 2012. Alzheimers Res Ther. 2013;5(Suppl 1):S5.
32. Zuidema SU, Johansson A, Selbæk G, et al. A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practice. Int Psychogeriatr. 2015;27(11):1849-1859.
33. Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762-769. Detroit Expert Panel on Assessment and Management of Neuropsychiatric Symptoms of Dementia
34. Cummings J, Mintzer J, Brodaty H, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr. 2015;27 (1):7-17.
35. McClam TD, Marano CM, Rosenberg PB, et al. Interventions for neuropsychiatric symptoms in neurocognitive impairment due to Alzheimer's disease: a review of the literature. Harv Rev Psychiatry. 2015;23(5):377-393.
36. Koponen M, Taipale H, Tanskanen A, et al. Long-term use of antipsychotics among community-dwelling persons with Alzheimer's disease: A nationwide register-based study. Eur Neuropsychopharmacol. 2015;25(10):1706-1713.
37. Bishara D, Taylor D, Howard RJ, et al. Expert opinion on the management of behavioural and psychological symptoms of dementia (BPSD) and investigation into prescribing practices in the UK. Int J Geriatr Psychiatry. 2009;24(9):944-954.
38. Rattinger GB, Burcu M, Dutcher SK, et al. Pharmacotherapeutic management of dementia across settings of care. J Am Geriatr Soc. 2013;61(5):723-733.
39. Xiao H, Su Y, Cao X, et al. A meta-analysis of mood stabilizers for Alzheimer's disease. J Huazhong Univ Sci Technolog Med Sci. 2010;30(5):652-658.
40. Tampi RR, Tampi DJ. Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2014;29(7):565-574.
41. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38(5):553-563.
42. Yury CA, Fisher JE. Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia. Psychother Psychosom. 2007;76(4):213-218.
43. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006;1:CD003476.
44. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Jama. 2005;294(15):1934-1943.
45. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191-210.
46. Ma H, Huang Y, Cong Z, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42 (3):915-937.
47. Tan L, Tan L, Wang HF, et al. Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis. Alzheimers Res Ther. 2015;7(1):20.
48. Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438-445.
49. Jeste DV, Blazer D, Casey D, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957-970.
50. Madhusoodanan S, Ting MB. Pharmacological management of behavioral symptoms associated with dementia. World J Psychiatry. 2014;4(4):72-79.
51. Ismail Z, Nguyen MQ, Fischer CE, et al. Neurobiology of delusions in Alzheimer's disease. Curr Psychiatry Rep. 2011;13(3):211-218.
52. Whitehead D, Tunnard C, Hurt C, et al. Frontotemporal atrophy associated with paranoid delusions in women with Alzheimer's disease. Int Psychogeriatr. 2012;24(1):99-107.
53. Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer's disease: past, present and future. Neuropharmacology. 2014;76 Pt A:27-50.
54. Martorana A, Esposito Z, Koch G. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? CNS Neurosci Ther. 2010;16(4):235-245.
55. Xu Y, Yan J, Zhou P, et al. Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease. Prog Neurobiol. 2012;97(1):1-13.
56. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res. 2011;221(2):555-563.
57. Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer's disease. Arch Pharm Res. 2013;36(4):375-399.
58. Tata AM, Velluto L, D'Angelo C, et al. Cholinergic system dysfunction and neurodegenerative diseases: cause or effect? CNS Neurol Disord Drug Targets. 2014;13(7):1294-1303.
59. Kumar A, Singh A. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67 (2):195-203.
60. Contestabile A. The history of the cholinergic hypothesis. Behav Brain Res. 2011;221(2):334-340.
61. Dumas JA, Newhouse PA. The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. Pharmacol Biochem Behav. 2011;99(2):254-261.
62. Pinto T, Lanctôt KL, Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type. Ageing Res Rev. 2011;10(4):404-412.
63. Dagyte G, Den Boer JA, Trentani A. The cholinergic system and depression. Behav Brain Res. 2011;221(2):574-582.
64. Engelborghs S, Vloeberghs E, Le Bastard N, et al. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochem Int. 2008;52(6):1052-1060.
65. Vermeiren Y, Van Dam D, Aerts T, et al. Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease. J Alzheimers Dis. 2014;41(3):819-833.
66. Vermeiren Y, Van Dam D, Aerts T, et al. The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther. 2015;7(1):7.
67. Hirao K, Pontone GM, Smith GS. Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. Neurosci Biobehav Rev. 2015;49:157-170.
68. Solas M, Puerta E, Ramirez MJ. Treatment options in Alzheimer's disease: the GABA story. Curr Pharm Des. 2015 Sep 14;21:4960-4971. [Epub ahead of print].
69. Ross JA, McGonigle P, Van Bockstaele EJ. Locus coeruleus, norepinephrine and Aβ peptides in Alzheimer's disease. Neurobiology of Stress. 2015;2:73-84.
70. Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia. 2005;43(3):442-449.
71. Proitsi P, Lupton MK, Reeves SJ, et al. Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiol Aging. 2012;33(4):791-803.
72. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr. 2014;19(2):121-133.
73. Garcia-Alloza M, Tsang SW, Gil-Bea FJ, et al. Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Neurobiol Aging. 2006;27(8):1110-1117.
74. Pytliak M, Vargová V, Mechírová V, et al. Serotonin receptors - from molecular biology to clinical applications. Physiol Res. 2011;60 (1):15-25.
75. Hornung J-P. The human raphe nuclei and the serotonergic system. J Chem Neuroanat. 2003;26(4):331-343.
76. Kroeze Y, Zhou H, Homberg JR. The genetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2012;136(3):375-400.
77. Rodríguez JJ, Noristani HN, Verkhratsky A. The serotonergic system in ageing and Alzheimer's disease. Prog Neurobiol. 2012;99(1):15-41.
78. Seyedabadi M, Fakhfouri G, Ramezani V, et al. The role of serotonin in memory: interactions with neurotransmitters and downstream signaling. Exp Brain Res. 2014;232(3):723-738.
79. Meneses A. Serotonin, neural markers, and memory. Front Pharmacol. 2015;6:143.
80. Meneses A. 5-HT systems: emergent targets for memory formation and memory alterations. Rev Neurosci. 2013;24(6):629-664.
81. Comai S, Tau M, Gobbi G. The psychopharmacology of aggressive behavior: a translational approach: part 1: neurobiology. J Clin Psychopharmacol. 2012;32(1):83-94.
82. Lanctôt KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2001;13(1):5-21.
83. Pritchard AL, Pritchard CW, Bentham P, et al. Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement Geriatr Cogn Disord. 2007;24(3):201-206.
84. Ramanathan S, Glatt SJ. Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis. Am J Geriatr Psychiatry. 2009;17(10):839-846.
85. Fidalgo S, Ivanov DK, Wood SH. Serotonin: from top to bottom. Biogerontology. 2013;14(1):21-45.
86. Meneses A. Do serotonin(1-7) receptors modulate short and longterm memory? Neurobiol Learn Mem. 2007;87(4):561-572.
87. Perez-Garcia G, Meneses A. Memory formation, amnesia, improved memory and reversed amnesia: 5-HT role. Behav Brain Res. 2008;195(1):17-29.
88. Cirrito JR, Disabato BM, Restivo JL, et al. Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A. 2011;108(36):14968-14973.
89. Sheline YI, West T, Yarasheski K, et al. An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014;6(236):236re4.
90. Hashimoto G, Sakurai M, Teich AF, et al. 5-HT receptor stimulation leads to soluble AβPPα production through MMP-9 upregulation. J Alzheimers Dis. 2012;32(2):437-445.
91. Tesseur I, Pimenova AA, Lo AC, et al. Chronic 5-HT4 receptor activation decreases Aβ production and deposition in hAPP/PS1 mice. Neurobiol Aging. 2013;34(7):1779-1789.
92. Giannoni P, Gaven F, De Bundel D, et al. Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer's disease. Front Aging Neurosci. 2013;5:96.
93. Pimenova AA, Thathiah A, De Strooper B, et al. Regulation of amyloid precursor protein processing by serotonin signaling. PLoS One. 2014;9(1):e87014.
94. Geldenhuys WJ, Van Der Schyf CJ. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease. Expert Rev Neurother. 2009;9(7):1073-1085.
95. Bali A, Singh S. Serotonergic 5-HT6 receptor antagonists: heterocyclic chemistry and potential therapeutic significance. Curr Top Med Chem. 2015;15(17):1643-1662.
96. Wicke K, Haupt A, Bespalov A. Investigational drugs targeting 5- HT6 receptors for the treatment of Alzheimer's disease. Expert Opin Investig Drugs. 2015;24(12):1515-1528.
97. Wilkinson D, Windfeld K, Colding-Jørgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebocontrolled phase 2 trial. Lancet Neurol. 2014;13(11):1092-1099.
98. Meneses A. Memory formation and memory alterations: 5-HT6 and 5-HT7 receptors, novel alternative. Rev Neurosci. 2014;25(3):325-356.
99. Terry AV Jr, Buccafusco JJ, Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res. 2008;195(1):30-38.
100. Ramirez MJ, Lai MK, Tordera RM, et al. Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status. Drugs. 2014;74(7):729-736.
101. Claeysen S, Bockaert J, Giannoni P. Serotonin: a new hope in Alzheimer's disease? ACS Chem Neurosci. 2015;6(7):940-943.
102. Herrmann N, Black SE, Chow T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry. 2012;20(9):789-797.
103. Hughes LE, Rittman T, Regenthal R, et al. Improving response inhibition systems in frontotemporal dementia with citalopram. Brain. 2015;138(Pt 7):1961-1975.
104. Flo E, Gulla C, Husebo BS. Effective pain management in patients with dementia: benefits beyond pain? Drugs Aging. 2014;31 (12):863-871.
105. Gilmartin JF, Väätäinen S, Törmälehto S, et al. Depressive symptoms are associated with analgesic use in people with Alzheimer's disease: Kuopio ALSOVA study. PLoS One. 2015;10(2):e0117926.
106. Kuroki T, Nagao N, Nakahara T. Neuropharmacology of secondgeneration antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res. 2008;172:199-212.
107. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011;11(1):59-67.
108. Meltzer HY. Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb Exp Pharmacol. 2012;212:87-124.
109. Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26(3):169-183.
110. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;(2): CD008191.
111. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry. 1990;157:894-901.
112. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159(3):460-465.
113. Moretti R, Torre P, Antonello RM, et al. Depression and Alzheimer's disease: symptom or comorbidity? Am J Alzheimers Dis Other Demen. 2002;17(6):338-344.
114. Scharre DW, Davis RA, Warner JL, et al. A pilot open-label trial of citalopram for restless activity and aberrant motor behaviors in Alzheimer disease. Am J Geriatr Psychiatry. 2003;11(6):687-691.
115. Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007;15(11):942-952.
116. Siddique H, Hynan LS, Weiner MF. Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. J Clin Psychiatry. 2009;70 (6):915-918.
117. Culo S, Mulsant BH, Rosen J, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord. 2010;24(4):360-364.
118. Barak Y, Plopski I, Tadger S, et al. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. Int Psychogeriatr. 2011;23(9):1515-1519.
119. Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. Jama. 2014;311(7):682-691.
120. Shua-Haim JR, Shua-Haim V, Ross JS. Combination therapy with donepezil and sertraline in the treatment of Alzheimer's disease. Alzheimers Reports. 1998;1(5):303-308.
121. Gaber S, Ronzoni S, Bruno A, et al. Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia. Arch Gerontol Geriatr. 2001;Suppl.: 7:159-162.
122. Lanctôt KL, Herrmann N, Van Reekum R, et al. Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. Int J Geriatr Psychiatry. 2002;17(6):531-541.
123. Finkel SI, Mintzer JE, Dysken M, et al. A randomized, placebocontrolled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004;19(1):9-18.
124. Olafsson K, Jørgensen S, Jensen HV, et al. Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebocontrolled study. Acta Psychiatr Scand. 1992;85(6):453-456.
125. Teranishi M, Kurita M, Nishino S, et al. Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial. J Clin Psychopharmacol. 2013;33(5):600-607.
126. Ramadan FH, Naughton BJ, Bassanelli AG. Treatment of verbal agitation with a selective serotonin reuptake inhibitor. J Geriatr Psychiatry Neurol. 2000;13(2):56-59.
127. Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49 (1):13-19.
128. Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl). 2004;172(4):400-408.
129. Burke WJ, Dewan V, Wengel SP, et al. The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia. Int J Geriatr Psychiatry. 1997;12(5):519-525.
130. Lebert F, Pasquier F, Petit H. Behavioral effects of trazodone in Alzheimer's disease. J Clin Psychiatry. 1994;55(12):536-538.
131. Sultzer DL, Gray KF, Gunay I, et al. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry. 1997;5(1):60-69.
132. Sultzer DL, Gray KF, Gunay I, et al. Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia? J Am Geriatr Soc. 2001;49(10):1294-1300.
133. Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55 (9):1271-1278.
134. Lebert F, Stekke W, Hasenbroekx C, et al. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17(4):355-359.
135. Bergh S, Selbæk G, Engedal K. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. Bmj. 2012;344:e1566.
136. Rosenberg PB, Drye LT, Porsteinsson AP, et al. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatr. 2015;27(12):2059-2067.
137. Bardell A, Lau T, Fedoroff JP. Inappropriate sexual behavior in a geriatric population. Int Psychogeriatr. 2011;23(7):1182-1188.
138. Stubbs B. Displays of inappropriate sexual behaviour by patients with progressive cognitive impairment: the forgotten form of challenging behaviour? J Psychiatr Ment Health Nurs. 2011;18(7):602-607.
139. Joller P, Gupta N, Seitz DP, et al. Approach to inappropriate sexual behaviour in people with dementia. Can Fam Physician. 2013;59 (3):255-260.
140. Tosto G, Talarico G, Lenzi GL, et al. Effect of citalopram in treating hypersexuality in an Alzheimer's disease case. Neurol Sci. 2008;29 (4):269-270.
141. Chen ST. Treatment of a patient with dementia and inappropriate sexual behaviors with citalopram. Alzheimer Dis Assoc Disord. 2010;24(4):402-403.
142. Kim KY, Bader GM, Jones E. Citalopram for verbal agitation in patients with dementia. J Geriatr Psychiatry Neurol. 2000;13 (2):53-55.
143. Camargos EF, Louzada LL, Quintas JL, et al. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry. 2014;22(12):1565-1574.
144. McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer's disease. Cochrane Database Syst Rev. 2014;3:CD009178.
145. Martinon-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev. 2004;4:CD004990.
146. Leong C. Antidepressants for depression in patients with dementia: a review of the literature. Consult Pharm. 2014;29(4):254-263.
147. Bains J, Birks J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev. 2002;4:CD003944.
148. Thompson S, Herrmann N, Rapoport MJ, et al. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. Can J Psychiatry. 2007;52(4):248-255.
149. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59(4):577-585.
150. Sepehry AA, Lee PE, Hsiung GY, et al. Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. Drugs Aging. 2012;29(10):793-806.
151. Reifler BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry. 1989;146(1):45-49.
152. Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand. 1992;86 (2):138-145.
153. Volicer L, Rheaume Y, Cyr D. Treatment Of Depression In Advanced Alzheimers-Disease Using Sertraline. J Geriatr Psychiatry Neurol. 1994;7(4):227-229.
154. Petracca G, Tesón A, Chemerinski E, et al. A double-blind placebocontrolled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1996;8 (3):270-275.
155. Taragano FE, Lyketsos CG, Mangone CA, et al. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics. 1997;38(3):246-252.
156. Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry. 1998;13 (2):100-108.
157. Magai C, Kennedy G, Cohen CI, et al. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry. 2000;8 (1):66-74.
158. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebocontrolled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr. 2001;13(2):233-240.
159. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60(7):737-746.
160. Mizukami K, Tanaka Y, Asada T. Efficacy of milnacipran on the depressive state in patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(7):1342-1346.
161. De Vasconcelos Cunha UG, Lopes Rocha F, Avi La De Melo R, et al. A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. Dement Geriatr Cogn Disord. 2007;24(1):36-41.
162. Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010;18(4):332-340.
163. Rosenberg PB, Drye LT, Martin BK, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18(2):136-145.
164. Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378 (9789):403-411.
165. Banerjee S, Hellier J, Romeo R, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial-a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess. 2013;17(7):1-166.
166. Coupland CA, Dhiman P, Barton G, et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol Assess. 2011;15(28):1-iv.
167. Diniz BS. Reynolds CF III. Major depressive disorder in older adults: benefits and hazards of prolonged treatment. Drugs Aging. 2014;31(9):661-669.
168. Sultana J, Spina E, Trifirò G. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opin Drug Metab Toxicol. 2015;11(6):883-892.
169. Spigset O, Wilhelmsson C, Mjörndal T, et al. Low serum sodium concentrations during treatment with citalopram in elderly patients: relationship to serum citalopram levels and to platelet serotonin 5-HT2A receptor status. J Clin Psychopharmacol. 2000;20 (5):582-584.
170. Soysal P, Isik AT. Severe hyponatremia due to escitalopram treatment in an elderly adult with Alzheimer's disease. J Am Geriatr Soc. 2014;62(12):2462-2463.
171. Tsai PH, Chen HC, Liao SC, et al. Recurrent escitalopram-induced hyponatremia in an elderly woman with dementia with Lewy bodies. Gen Hosp Psychiatry. 2012;34(1):101.e5-7.
172. Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). [2011; cited 2015 Nov 08]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.
173. Drye LT, Spragg D, Devanand DP, et al. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. PLoS One. 2014;9(6):e98426.
174. Lee YC, Lin CH, Lin MS, et al. Effects of selective serotonin reuptake inhibitors versus tricyclic antidepressants on cerebrovascular events: a nationwide population-based cohort study. J Clin Psychopharmacol. 2013;33(6):782-789.
175. Trifirò G, Dieleman J, Sen EF, et al. Risk of ischemic stroke associated with antidepressant drug use in elderly persons. J Clin Psychopharmacol. 2010;30(3):252-258.
176. Wu CS, Chang CM, Chen CY, et al. Association between antidepressants and venous thromboembolism in Taiwan. J Clin Psychopharmacol. 2013;33(1):31-37.
177. Wang MT, Chu CL, Yeh CB, et al. Antidepressant use and risk of recurrent stroke: a population-based nested case-control study. J Clin Psychiatry. 2015;76(7):e877-885.
178. Thorlund K, Druyts E, Wu P, et al. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc. 2015;63(5):1002-1009.
179. Wang J, Yu JT, Wang HF, et al. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86 (1):101-109.
180. Magierski R, Sobow T. Benefits and risks of add-on therapies for Alzheimer's disease. Neurodegener Dis Manag. 2015;5(5):445-462.
181. Bharadwaj PR, Bates KA, Porter T, et al. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases. Transl Psychiatry. 2013;3: e332.
182. Chau S, Herrmann N, Ruthirakuhan MT, et al. Latrepirdine for Alzheimer's disease. Cochrane Database Syst Rev. 2015;4: CD009524.
183. Galimberti D, Scarpini E. Idalopirdine as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2015;24 (7):981-987.
184. Kołaczkowski M, Marcinkowska M, Bucki A, et al. Novel arylsulfonamide derivatives with 5-HT6/5-HT7 receptor antagonism targeting behavioral and psychological symptoms of dementia. J Med Chem. 2014;57(11):4543-4557.
185. Kołaczkowski M, Mierzejewski P, Bieńkowski P, et al. ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility. Br J Pharmacol. 2014;171(4):973-984.
186. Kołaczkowski M, Marcinkowska M, Bucki A, et al. Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia. Eur J Med Chem. 2015;92:221-235.
187. Lyketsos CG, Carrillo MC, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement. 2011;7(5):532-539.
188. De Medeiros K, Robert P, Gauthier S, et al. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr. 2010;22(6):984-994.
189. Forrester SN, Gallo JJ, Smith GS, et al. Patterns of neuropsychiatric symptoms in mild cognitive impairment and risk of dementia. Am J Geriatr Psychiatry. 2016;24(2):117-125.
190. Leoutsakos JM, Forrester SN, Lyketsos CG, et al. Latent classes of neuropsychiatric symptoms in NACC controls and conversion to mild cognitive impairment or dementia. J Alzheimers Dis. 2015;48 (2):483-493.
191. David ND, Lin F, Porsteinsson AP; Alzheimer's Disease Neuroimaging Initiative. Trajectories of neuropsychiatric symptoms and cognitive decline in mild cognitive impairment. Am J Geriatr Psychiatry. 2016;24(1):70-80.
192. Trzepacz PT, Cummings J, Konechnik T, et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. Int Psychogeriatr. 2013;25(5):707-719.